Panagiota Pagoni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Panagiota Pagoni has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Evie Stergiakouli
Cleft Collective, University of Bristol, Bristol, UK
7 shared publications Evie Stergiakouli
MRC Integrative Epidemiology Unit at the University of Bristol, Oakfield House, Bristol, UK
5 shared publicationsGeorge Davey Smith
MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol
4 shared publications- George Davey Smith
University of Bristol
4 shared publications - Alexandra Havdahl
PsychGen Centre for Genetic Epidemiology and Mental Health, Division of Public Health and Prevention, Norwegian Institute of Public Health, Oslo, Norway
3 shared publications - Christina Dardani
University of Bristol
3 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Vol. 55 (3)
Comorbidity of asthma and attention deficit hyperactivity disorder in childhood: causal, shared early-life risk factors, or shared genetic liability?
The positive association between childhood asthma and attention deficit hyperactivity disorder (ADHD) has not been adequately explained. We aimed to investigate whether it is causal or whether shared genetics and/or shared early-life risk factors explain the link. We used a two-sample Mendelian randomization (MR) to test whether there is a causal relationship between asthma and ADHD. In the Avon Longitudinal Study of Parents and Children (ALSPAC), we defined doctor-diagnosed asthma, its endotypes according to atopy determined by skin-prick tests, and the risk of ADHD by using the Strengths and Difficulties Questionnaire, all at 7 years of age. We explored whether the asthma-ADHD association was attenuated when controlling for an extensive number of early-life risk factors (N = 7165). Child polygenic risk scores (PRSs) for asthma and ADHD were calculated by using published genome-wide association studies across seven P-value thresholds (<5 × 10-8 to <.5) (N = 5425-5503). We found little evidence of a causal effect between asthma and ADHD in both directions. In ALSPAC, asthma [odds ratio (OR) 1.35, 95% confidence interval (CI) 1.10 - 1.65], particularly non-atopic asthma (OR 1.51, 95% CI 1.09 - 2.08), was associated with ADHD in crude models, while atopic asthma was not (OR 1.00, 95% CI 0.69 - 1.45). These associations were largely attenuated after adjusting for 15 shared early-life risk factors (OR 1.14, 95% CI 0.92 - 1.41 for asthma and OR 1.24, 95% CI 0.88 - 1.74 for non-atopic asthma). There was little evidence of association between asthma PRSs and ADHD at any P-value threshold. We found evidence of an association between ADHD PRSs and asthma and non-atopic asthma at most thresholds; the strongest association was at P < 5 × 10-3 (OR 1.12, 95% CI 1.04 - 1.22, P = .004) for asthma and at P < 5 × 10-2 (OR 1.18, 95% CI 1.04 - 1.34, P = .01) for non-atopic asthma. The association between asthma and ADHD in childhood is unlikely to be causal and is largely explained by shared early-life risk factors, with some evidence for a shared genetic background.
- 17 April 2026
- Vol. 55 (3)
Open AccessComorbidity of asthma and attention deficit hyperactivity disorder in childhood: causal, shared early-life risk factors, or shared genetic liability?
The positive association between childhood asthma and attention deficit hyperactivity disorder (ADHD) has not been adequately explained. We aimed to investigate whether it is causal or whether shared genetics and/or shared early-life risk factors explain the link. We used a two-sample Mendelian randomization (MR) to test whether there is a causal relationship between asthma and ADHD. In the Avon Longitudinal Study of Parents and Children (ALSPAC), we defined doctor-diagnosed asthma, its endotypes according to atopy determined by skin-prick tests, and the risk of ADHD by using the Strengths and Difficulties Questionnaire, all at 7 years of age. We explored whether the asthma-ADHD association was attenuated when controlling for an extensive number of early-life risk factors (N = 7165). Child polygenic risk scores (PRSs) for asthma and ADHD were calculated by using published genome-wide association studies across seven P-value thresholds (<5 × 10-8 to <.5) (N = 5425-5503). We found little evidence of a causal effect between asthma and ADHD in both directions. In ALSPAC, asthma [odds ratio (OR) 1.35, 95% confidence interval (CI) 1.10 - 1.65], particularly non-atopic asthma (OR 1.51, 95% CI 1.09 - 2.08), was associated with ADHD in crude models, while atopic asthma was not (OR 1.00, 95% CI 0.69 - 1.45). These associations were largely attenuated after adjusting for 15 shared early-life risk factors (OR 1.14, 95% CI 0.92 - 1.41 for asthma and OR 1.24, 95% CI 0.88 - 1.74 for non-atopic asthma). There was little evidence of association between asthma PRSs and ADHD at any P-value threshold. We found evidence of an association between ADHD PRSs and asthma and non-atopic asthma at most thresholds; the strongest association was at P < 5 × 10-3 (OR 1.12, 95% CI 1.04 - 1.22, P = .004) for asthma and at P < 5 × 10-2 (OR 1.18, 95% CI 1.04 - 1.34, P = .01) for non-atopic asthma. The association between asthma and ADHD in childhood is unlikely to be causal and is largely explained by shared early-life risk factors, with some evidence for a shared genetic background.
- Open Access
- 6 January 2024
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 39 (3) , 257-270
Meta-regression of genome-wide association studies to estimate age-varying genetic effects
Fixed-effect meta-analysis has been used to summarize genetic effects on a phenotype across multiple Genome-Wide Association Studies (GWAS) assuming a common underlying genetic effect. Genetic effects may vary with age (or other characteristics), and not allowing for this in a GWAS might lead to bias. Meta-regression models between study heterogeneity and allows effect modification of the genetic effects to be explored. The aim of this study was to explore the use of meta-analysis and meta-regression for estimating age-varying genetic effects on phenotypes. With simulations we compared the performance of meta-regression to fixed-effect and random -effects meta-analyses in estimating (i) main genetic effects and (ii) age-varying genetic effects (SNP by age interactions) from multiple GWAS studies under a range of scenarios. We applied meta-regression on publicly available summary data to estimate the main and age-varying genetic effects of the FTO SNP rs9939609 on Body Mass Index (BMI). Fixed-effect and random-effects meta-analyses accurately estimated genetic effects when these did not change with age. Meta-regression accurately estimated both main genetic effects and age-varying genetic effects. When the number of studies or the age-diversity between studies was low, meta-regression had limited power. In the applied example, each additional minor allele (A) of rs9939609 was inversely associated with BMI at ages 0 to 3, and positively associated at ages 5.5 to 13. Our findings challenge the assumption that genetic effects are consistent across all ages and provide a method for exploring this. GWAS consortia should be encouraged to use meta-regression to explore age-varying genetic effects.
- 6 January 2024
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 39 (3) , 257-270
Open AccessMeta-regression of genome-wide association studies to estimate age-varying genetic effects
Fixed-effect meta-analysis has been used to summarize genetic effects on a phenotype across multiple Genome-Wide Association Studies (GWAS) assuming a common underlying genetic effect. Genetic effects may vary with age (or other characteristics), and not allowing for this in a GWAS might lead to bias. Meta-regression models between study heterogeneity and allows effect modification of the genetic effects to be explored. The aim of this study was to explore the use of meta-analysis and meta-regression for estimating age-varying genetic effects on phenotypes. With simulations we compared the performance of meta-regression to fixed-effect and random -effects meta-analyses in estimating (i) main genetic effects and (ii) age-varying genetic effects (SNP by age interactions) from multiple GWAS studies under a range of scenarios. We applied meta-regression on publicly available summary data to estimate the main and age-varying genetic effects of the FTO SNP rs9939609 on Body Mass Index (BMI). Fixed-effect and random-effects meta-analyses accurately estimated genetic effects when these did not change with age. Meta-regression accurately estimated both main genetic effects and age-varying genetic effects. When the number of studies or the age-diversity between studies was low, meta-regression had limited power. In the applied example, each additional minor allele (A) of rs9939609 was inversely associated with BMI at ages 0 to 3, and positively associated at ages 5.5 to 13. Our findings challenge the assumption that genetic effects are consistent across all ages and provide a method for exploring this. GWAS consortia should be encouraged to use meta-regression to explore age-varying genetic effects.
- Open Access
A systematic literature review of methodological approaches, challenges, and opportunities in the application of Mendelian randomisation to lifecourse epidemiology
Background Diseases diagnosed in adulthood may have antecedents throughout – including prenatal – life. Gaining a better understanding of how exposures at different stages in the lifecourse influence health outcomes is key to elucidating the potential benefits of specific disease prevention strategies. However, confounding is highly likely in studies with earlier life or time-varying exposures. Mendelian randomisation (MR) is therefore increasingly used to estimate causal effects of exposures across the lifecourse on later life outcomes. Methods This systematic literature review aims to identify MR methods used to perform lifecourse investigations and review previous work that has utilised MR to elucidate the effects of factors acting at different stages of the lifecourse. We conducted a systematic search in PubMed, Embase, Medline and MedRXiv databases to comprehensively obtain lifecourse epidemiology studies that have employed MR. Results Thirteen methodological studies were identified. Four studies focused on the impact of time-varying exposures on the interpretation of “standard” MR techniques, five presented methods for analysing repeat measures of the same exposure, and four described novel methodological approaches to handling parental exposures in relation to offspring outcomes. A further 84 studies presented the results of an applied research question with relevance to lifecourse epidemiology. Over half of these estimated effects in a single generation and were largely confined to the exploration of questions regarding body composition. Of the one generational studies employed in this review, 59% estimated the effect of exposures at birth, birth to/and childhood, birth to/and adolescence or birth to/and adulthood, 30% at childhood, childhood to/and adolescence or childhood to/and adulthood, and 11% at adolescence or adulthood. The remaining looked across two generations. These estimated effects of maternal exposures, with one study additionally examining paternal exposures, in relation to offspring outcomes. Conclusion There is a growing body of research focused on the development and application of MR methods to address lifecourse research questions. The possibility that genetic effects have different levels of importance in the progression of an exposure at different ages should be more commonly considered for application in an MR context. Limitations exist, however, specifically regarding data constraints.
Open AccessA systematic literature review of methodological approaches, challenges, and opportunities in the application of Mendelian randomisation to lifecourse epidemiology
Background Diseases diagnosed in adulthood may have antecedents throughout – including prenatal – life. Gaining a better understanding of how exposures at different stages in the lifecourse influence health outcomes is key to elucidating the potential benefits of specific disease prevention strategies. However, confounding is highly likely in studies with earlier life or time-varying exposures. Mendelian randomisation (MR) is therefore increasingly used to estimate causal effects of exposures across the lifecourse on later life outcomes. Methods This systematic literature review aims to identify MR methods used to perform lifecourse investigations and review previous work that has utilised MR to elucidate the effects of factors acting at different stages of the lifecourse. We conducted a systematic search in PubMed, Embase, Medline and MedRXiv databases to comprehensively obtain lifecourse epidemiology studies that have employed MR. Results Thirteen methodological studies were identified. Four studies focused on the impact of time-varying exposures on the interpretation of “standard” MR techniques, five presented methods for analysing repeat measures of the same exposure, and four described novel methodological approaches to handling parental exposures in relation to offspring outcomes. A further 84 studies presented the results of an applied research question with relevance to lifecourse epidemiology. Over half of these estimated effects in a single generation and were largely confined to the exploration of questions regarding body composition. Of the one generational studies employed in this review, 59% estimated the effect of exposures at birth, birth to/and childhood, birth to/and adolescence or birth to/and adulthood, 30% at childhood, childhood to/and adolescence or childhood to/and adulthood, and 11% at adolescence or adulthood. The remaining looked across two generations. These estimated effects of maternal exposures, with one study additionally examining paternal exposures, in relation to offspring outcomes. Conclusion There is a growing body of research focused on the development and application of MR methods to address lifecourse research questions. The possibility that genetic effects have different levels of importance in the progression of an exposure at different ages should be more commonly considered for application in an MR context. Limitations exist, however, specifically regarding data constraints.
- Open Access
Meta-regression of Genome-Wide Association Studies to estimate age-varying genetic effects
Background: Fixed-effect meta-analysis has been used to summarize genetic effects on a phenotype across multiple Genome-Wide Association Studies (GWAS) assuming a common underlying genetic effect. Genetic effects may vary with age, therefore meta-analysing GWAS of age-diverse samples could be misleading. Meta-regression allows adjustment for study specific characteristics and models heterogeneity between studies. The aim of this study was to explore the use of meta-analysis and meta-regression for estimating age-varying genetic effects on phenotypes. Methods: With simulations we compared the performance of meta-regression to fixed-effect and random -effects meta-analyses in estimating (i) main genetic effects and (ii) age-varying genetic effects (SNP by age interactions) from multiple GWAS studies under a range of scenarios. We applied meta-regression on publicly available summary data to estimate the main and age-varying genetic effects of the FTO SNP rs9939609 on Body Mass Index (BMI). Results: Fixed-effect and random-effects meta-analyses accurately estimated genetic effects when these did not change with age. Meta-regression accurately estimated both the main genetic effects and the age-varying genetic effects. When the number of studies or the age-diversity between studies was low, meta-regression had limited power. In the applied example, each additional minor allele (A) of rs9939609 was inversely associated with BMI at ages 0 to 3, and positively associated at ages 5.5 to 13. This is similar to the association that has been previously reported by a study that used individual participant data. Conclusions: GWAS using summary statistics from age-diverse samples should consider using meta-regression to explore age-varying genetic effects. KEY MESSAGES: Meta-analysis has been used to summarize genetic effects on a phenotype across multiple Genome-Wide Association Studies (GWAS) assuming a common underlying genetic effect for all studies. However, genetic effects may vary with age, therefore meta-analysing GWAS of age-diverse samples could produce misleading results. Meta-regression could be used to relate observed between-study heterogeneity to study characteristics such as age. Therefore, meta-regression could be used to combine summary level GWAS data to provide evidence for any age-varying genetic effects. This simulation study shows that when genetic effects vary with age, meta-regression provides unbiased estimates of main and age-varying genetic effects. The precision of the estimates depends on the number of studies included, and the diversity in age between them. The applied example using publicly available summary data, supported the simulation study. By applying meta-regression, we observed a previously reported age-varying association between each additional minor allele (A) of rs9939609 and BMI; an inverse at ages 0 to 3 and a positive association at ages 5.5 to 13.Similar association has been previously reported by a study that used individual participant data.
Open AccessMeta-regression of Genome-Wide Association Studies to estimate age-varying genetic effects
Background: Fixed-effect meta-analysis has been used to summarize genetic effects on a phenotype across multiple Genome-Wide Association Studies (GWAS) assuming a common underlying genetic effect. Genetic effects may vary with age, therefore meta-analysing GWAS of age-diverse samples could be misleading. Meta-regression allows adjustment for study specific characteristics and models heterogeneity between studies. The aim of this study was to explore the use of meta-analysis and meta-regression for estimating age-varying genetic effects on phenotypes. Methods: With simulations we compared the performance of meta-regression to fixed-effect and random -effects meta-analyses in estimating (i) main genetic effects and (ii) age-varying genetic effects (SNP by age interactions) from multiple GWAS studies under a range of scenarios. We applied meta-regression on publicly available summary data to estimate the main and age-varying genetic effects of the FTO SNP rs9939609 on Body Mass Index (BMI). Results: Fixed-effect and random-effects meta-analyses accurately estimated genetic effects when these did not change with age. Meta-regression accurately estimated both the main genetic effects and the age-varying genetic effects. When the number of studies or the age-diversity between studies was low, meta-regression had limited power. In the applied example, each additional minor allele (A) of rs9939609 was inversely associated with BMI at ages 0 to 3, and positively associated at ages 5.5 to 13. This is similar to the association that has been previously reported by a study that used individual participant data. Conclusions: GWAS using summary statistics from age-diverse samples should consider using meta-regression to explore age-varying genetic effects. KEY MESSAGES: Meta-analysis has been used to summarize genetic effects on a phenotype across multiple Genome-Wide Association Studies (GWAS) assuming a common underlying genetic effect for all studies. However, genetic effects may vary with age, therefore meta-analysing GWAS of age-diverse samples could produce misleading results. Meta-regression could be used to relate observed between-study heterogeneity to study characteristics such as age. Therefore, meta-regression could be used to combine summary level GWAS data to provide evidence for any age-varying genetic effects. This simulation study shows that when genetic effects vary with age, meta-regression provides unbiased estimates of main and age-varying genetic effects. The precision of the estimates depends on the number of studies included, and the diversity in age between them. The applied example using publicly available summary data, supported the simulation study. By applying meta-regression, we observed a previously reported age-varying association between each additional minor allele (A) of rs9939609 and BMI; an inverse at ages 0 to 3 and a positive association at ages 5.5 to 13.Similar association has been previously reported by a study that used individual participant data.
- Open Access
- 1 October 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-7
Exploring the causal effects of genetic liability to ADHD and Autism on Alzheimer’s disease
Few studies suggest possible links between attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and Alzheimer’s disease but they have been limited by small sample sizes, diagnostic and recall bias. We used two-sample Mendelian randomization (MR) to estimate the bidirectional causal association between genetic liability to ADHD and ASD on Alzheimer’s disease. In addition, we estimated the causal effects independently of educational attainment and IQ, through multivariable Mendelian randomization (MVMR). We employed genetic variants associated with ADHD (20,183 cases/35,191 controls), ASD (18,381 cases/27,969 controls), Alzheimer’s disease (71,880 cases/383,378 controls), educational attainment (n = 766,345) and IQ (n = 269,867) using the largest GWAS of European ancestry. There was limited evidence to suggest a causal effect of genetic liability to ADHD (odds ratio [OR] = 1.00, 95% CI: 0.98–1.02, P = 0.39) or ASD (OR = 0.99, 95% CI: 0.97–1.01, P = 0.70) on Alzheimer’s disease. Similar causal effect estimates were identified as direct effects, independent of educational attainment (ADHD: OR = 1.00, 95% CI: 0.99–1.01, P = 0.76; ASD: OR = 0.99, 95% CI: 0.98–1.00, P = 0.28) and IQ (ADHD: OR = 1.00, 95% CI: 0.99–1.02. P = 0.29; ASD: OR = 0.99, 95% CI: 0.98–1.01, P = 0.99). Genetic liability to Alzheimer’s disease was not found to have a causal effect on risk of ADHD or ASD (ADHD: OR = 1.12, 95% CI: 0.86–1.44, P = 0.37; ASD: OR = 1.19, 95% CI: 0.94–1.51, P = 0.14). We found limited evidence to suggest a causal effect of genetic liability to ADHD or ASD on Alzheimer’s disease; and vice versa.
- 1 October 2022
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-7
Open AccessExploring the causal effects of genetic liability to ADHD and Autism on Alzheimer’s disease
Few studies suggest possible links between attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and Alzheimer’s disease but they have been limited by small sample sizes, diagnostic and recall bias. We used two-sample Mendelian randomization (MR) to estimate the bidirectional causal association between genetic liability to ADHD and ASD on Alzheimer’s disease. In addition, we estimated the causal effects independently of educational attainment and IQ, through multivariable Mendelian randomization (MVMR). We employed genetic variants associated with ADHD (20,183 cases/35,191 controls), ASD (18,381 cases/27,969 controls), Alzheimer’s disease (71,880 cases/383,378 controls), educational attainment (n = 766,345) and IQ (n = 269,867) using the largest GWAS of European ancestry. There was limited evidence to suggest a causal effect of genetic liability to ADHD (odds ratio [OR] = 1.00, 95% CI: 0.98–1.02, P = 0.39) or ASD (OR = 0.99, 95% CI: 0.97–1.01, P = 0.70) on Alzheimer’s disease. Similar causal effect estimates were identified as direct effects, independent of educational attainment (ADHD: OR = 1.00, 95% CI: 0.99–1.01, P = 0.76; ASD: OR = 0.99, 95% CI: 0.98–1.00, P = 0.28) and IQ (ADHD: OR = 1.00, 95% CI: 0.99–1.02. P = 0.29; ASD: OR = 0.99, 95% CI: 0.98–1.01, P = 0.99). Genetic liability to Alzheimer’s disease was not found to have a causal effect on risk of ADHD or ASD (ADHD: OR = 1.12, 95% CI: 0.86–1.44, P = 0.37; ASD: OR = 1.19, 95% CI: 0.94–1.51, P = 0.14). We found limited evidence to suggest a causal effect of genetic liability to ADHD or ASD on Alzheimer’s disease; and vice versa.
- Open Access
- 14 May 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 104, 54-64
Causal effects of circulating cytokine concentrations on risk of Alzheimer’s disease and cognitive function
- 14 May 2022
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 104, 54-64
Open AccessCausal effects of circulating cytokine concentrations on risk of Alzheimer’s disease and cognitive function
- Open Access
Immunological pathways underlying autism: Findings from Mendelian randomization and genetic colocalisation analyses
Emerging evidence implicates the role of inflammation and immunity in autism. However, little is known about the involvement of specific immunological pathways and their causal role. In 18,381 autism cases and 27,969 controls from the PGC and the iPSYCH consortia, we investigated whether 15 cytokines implicated in the differentiation and function of CD4 + T cell subsets (T H 1, T H 2, T H 9, T FH , T H 17, T Reg ) could be causally linked to autism. Within a Mendelian randomization framework, we used protein quantitative trait loci (pQTLs; N=1,000-3,394) to assess the effects of genetically proxied levels of plasma cytokines on autism. We additionally used brain cortex expression quantitative trait loci (eQTLs; N= 6,601) to investigate whether genetically predicted expression of the genes encoding the cytokines of interest influence autism. We performed colocalisation to assess the possibility that the identified effects were confounded due to Linkage Disequilibrium (LD). We also assessed the possibility of reverse causation. We report consistent evidence for causal effects of genetically predicted levels of IFN-γR1, IL-12Rβ1 (T H 1), and IL-4RA, IL-5RA, IL-13RA1 (T H 2) on autism. We identified brain-specific effects of genetically predicted expression of IFNGR1, IL12RB1, IL23A , which in the case of IFNGR1 and IL23A were additionally supported by evidence suggestive of colocalisation. Findings appeared unlikely to be influenced by reverse causation. Our findings are consistent with a potentially causal effect of T H 1 and T H 2 pathway cytokines in autism, and further research is required to elucidate the pathways via which T H 1 and T H 2 influence its phenotypic presentation.
Open AccessImmunological pathways underlying autism: Findings from Mendelian randomization and genetic colocalisation analyses
Emerging evidence implicates the role of inflammation and immunity in autism. However, little is known about the involvement of specific immunological pathways and their causal role. In 18,381 autism cases and 27,969 controls from the PGC and the iPSYCH consortia, we investigated whether 15 cytokines implicated in the differentiation and function of CD4 + T cell subsets (T H 1, T H 2, T H 9, T FH , T H 17, T Reg ) could be causally linked to autism. Within a Mendelian randomization framework, we used protein quantitative trait loci (pQTLs; N=1,000-3,394) to assess the effects of genetically proxied levels of plasma cytokines on autism. We additionally used brain cortex expression quantitative trait loci (eQTLs; N= 6,601) to investigate whether genetically predicted expression of the genes encoding the cytokines of interest influence autism. We performed colocalisation to assess the possibility that the identified effects were confounded due to Linkage Disequilibrium (LD). We also assessed the possibility of reverse causation. We report consistent evidence for causal effects of genetically predicted levels of IFN-γR1, IL-12Rβ1 (T H 1), and IL-4RA, IL-5RA, IL-13RA1 (T H 2) on autism. We identified brain-specific effects of genetically predicted expression of IFNGR1, IL12RB1, IL23A , which in the case of IFNGR1 and IL23A were additionally supported by evidence suggestive of colocalisation. Findings appeared unlikely to be influenced by reverse causation. Our findings are consistent with a potentially causal effect of T H 1 and T H 2 pathway cytokines in autism, and further research is required to elucidate the pathways via which T H 1 and T H 2 influence its phenotypic presentation.
- 27 September 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e64-E64
44. INFLAMMATORY PATHWAYS TO AUTISM: EXPLORING CAUSALITY WITHIN A TWO-SAMPLE MENDELIAN RANDOMIZATION FRAMEWORK
- 27 September 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e64-E64
44. INFLAMMATORY PATHWAYS TO AUTISM: EXPLORING CAUSALITY WITHIN A TWO-SAMPLE MENDELIAN RANDOMIZATION FRAMEWORK
- Open Access
Parental inflammatory bowel disease and autism in the offspring: Triangulating the evidence using four complementary study designs
Importance: Evidence linking parental diagnoses of inflammatory bowel disease (IBD) with offspring autism is inconclusive. Objective: To investigate associations between parental diagnoses of IBD and offspring autism and elucidate their underlying aetiology by conducting four complementary studies. Design, Setting and Participants: (1) Nationwide population-based cohort study using Swedish registers to examine associations between parental IBD diagnoses and autism diagnoses in offspring, (2) Linkage disequilibrium (LD)-score regression to estimate the genetic correlation between the phenotypes. (3) Polygenic risk score (PRS) analyses in the Avon Longitudinal Study of Parents and Children (ALSPAC) to investigate associations between maternal genetic liability to IBD and autism factor mean score in offspring. (4) Two-sample Mendelian randomization (MR) to assess bidirectional causal links between genetic liability to IBD and autism. Results: Observational analyses provided evidence of an association between parental IBD diagnoses and offspring autism diagnosis in mutually adjusted models (maternal: OR= 1.32; 95% CI: 1.25 to 1.40; pPRS = 0.02; 95%CI: 0.003 to 0.05; p= 0.02; R 2 =0.06; Crohn’s: β PRS = 0.03; 95%CI: 0.01 to 0.05; p= 0.004; R 2 = 0.06; n= 7357, 50.3% male). MR analyses provided evidence of a potential causal effect of genetic liability for IBD, especially ulcerative colitis, on autism (OR MR = 1.03; 95%CI: 1.01 to 1.06). There was little evidence to suggest a causal effect of genetic liability to autism on risk of IBD, or a genetic correlation between the two conditions. Conclusions and relevance: Triangulating evidence from a nationwide register-based cohort study, genetic correlation, polygenic risk score analyses and MR, we found evidence of a potentially causal link between parental, particularly maternal, diagnoses and genetic liability to IBD and offspring autism. Perinatal immune system dysregulation, micronutrient malabsorption and anaemia may be implicated.
Open AccessParental inflammatory bowel disease and autism in the offspring: Triangulating the evidence using four complementary study designs
Importance: Evidence linking parental diagnoses of inflammatory bowel disease (IBD) with offspring autism is inconclusive. Objective: To investigate associations between parental diagnoses of IBD and offspring autism and elucidate their underlying aetiology by conducting four complementary studies. Design, Setting and Participants: (1) Nationwide population-based cohort study using Swedish registers to examine associations between parental IBD diagnoses and autism diagnoses in offspring, (2) Linkage disequilibrium (LD)-score regression to estimate the genetic correlation between the phenotypes. (3) Polygenic risk score (PRS) analyses in the Avon Longitudinal Study of Parents and Children (ALSPAC) to investigate associations between maternal genetic liability to IBD and autism factor mean score in offspring. (4) Two-sample Mendelian randomization (MR) to assess bidirectional causal links between genetic liability to IBD and autism. Results: Observational analyses provided evidence of an association between parental IBD diagnoses and offspring autism diagnosis in mutually adjusted models (maternal: OR= 1.32; 95% CI: 1.25 to 1.40; pPRS = 0.02; 95%CI: 0.003 to 0.05; p= 0.02; R 2 =0.06; Crohn’s: β PRS = 0.03; 95%CI: 0.01 to 0.05; p= 0.004; R 2 = 0.06; n= 7357, 50.3% male). MR analyses provided evidence of a potential causal effect of genetic liability for IBD, especially ulcerative colitis, on autism (OR MR = 1.03; 95%CI: 1.01 to 1.06). There was little evidence to suggest a causal effect of genetic liability to autism on risk of IBD, or a genetic correlation between the two conditions. Conclusions and relevance: Triangulating evidence from a nationwide register-based cohort study, genetic correlation, polygenic risk score analyses and MR, we found evidence of a potentially causal link between parental, particularly maternal, diagnoses and genetic liability to IBD and offspring autism. Perinatal immune system dysregulation, micronutrient malabsorption and anaemia may be implicated.